NYSE:MD - MEDNAX Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $18.95
  • Forecasted Upside: -27.23 %
  • Number of Analysts: 7
  • Breakdown:
  • 2 Sell Ratings
  • 4 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$26.04
▲ +0.62 (2.44%)
1 month | 3 months | 12 months
Get New MEDNAX Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MD

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$18.95
▼ -27.23% Downside Potential
This price target is based on 7 analysts offering 12 month price targets for MEDNAX in the last 3 months. The average price target is $18.95, with a high forecast of $26.00 and a low forecast of $14.00. The average price target represents a -27.23% upside from the last price of $26.04.
Hold
The current consensus among 7 contributing investment analysts is to hold stock in MEDNAX. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 3 sell ratings
9/14/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 3 sell ratings
12/13/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 7 hold ratings
  • 3 sell ratings
3/12/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 7 hold ratings
  • 3 sell ratings
6/10/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 6 hold ratings
  • 2 sell ratings
9/8/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 6 hold ratings
  • 2 sell ratings
12/7/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 6 hold ratings
  • 2 sell ratings
2/5/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 2 sell ratings
3/7/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 2 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/25/2021Credit Suisse GroupLower Price TargetOutperform$26.00 ➝ $25.00Low
i
2/19/2021CitigroupLower Price Target$24.00 ➝ $22.00Medium
i
2/19/2021Deutsche Bank AktiengesellschaftBoost Price TargetSell$14.00 ➝ $17.50High
i
1/5/2021TruistBoost Price Target$20.00 ➝ $26.00N/A
i
10/19/2020Deutsche Bank AktiengesellschaftDowngradeHold ➝ Sell$20.00 ➝ $12.00High
i
10/6/2020UBS GroupBoost Price TargetSell$11.00 ➝ $14.00High
i
6/8/2020BMO Capital MarketsBoost Price Target$16.00 ➝ $20.00Medium
i
6/8/2020Credit Suisse GroupBoost Price TargetOutperform$20.00 ➝ $24.00Low
i
5/29/2020MizuhoLower Price TargetNeutral$19.00 ➝ $17.00High
i
5/21/2020SunTrust BanksBoost Price TargetHold$15.00 ➝ $17.00Low
i
5/11/2020CfraLower Price TargetHold$22.00 ➝ $15.00Low
i
5/11/2020Credit Suisse GroupLower Price TargetOutperform$22.00 ➝ $20.00High
i
5/8/2020UBS GroupLower Price TargetSell$18.00 ➝ $11.00Low
i
5/8/2020Deutsche Bank AktiengesellschaftLower Price Target$24.00 ➝ $15.00Medium
i
4/21/2020Robert W. BairdLower Price TargetNeutral$21.00 ➝ $16.00High
i
4/13/2020SunTrust BanksLower Price TargetHold$22.00 ➝ $15.00Medium
i
3/26/2020Credit Suisse GroupLower Price TargetOutperform$29.00 ➝ $22.00Low
i
3/3/2020Robert W. BairdLower Price TargetNeutral$24.00 ➝ $21.00High
i
2/24/2020JPMorgan Chase & Co.Lower Price TargetNeutral$33.00 ➝ $20.00High
i
2/24/2020Credit Suisse GroupLower Price TargetOutperform$33.00 ➝ $29.00High
i
2/21/2020CitigroupLower Price TargetNeutral$29.00 ➝ $23.00High
i
Rating by Ralph Giacobbe at Citigroup Inc.
2/21/2020MizuhoLower Price TargetNeutral$25.00 ➝ $22.00High
i
Rating by Ann Hynes at Mizuho
1/3/2020Deutsche Bank AktiengesellschaftInitiated CoverageHold$34.00Low
i
1/3/2020CitigroupDowngradeBuy ➝ Neutral$29.00Medium
i
12/20/2019JPMorgan Chase & Co.Boost Price TargetNeutral$26.00 ➝ $33.00Low
i
12/18/2019SunTrust BanksBoost Price TargetHold$27.00 ➝ $30.00Low
i
12/12/2019Stifel NicolausUpgradeHold ➝ Buy$25.00 ➝ $33.00High
i
11/1/2019MizuhoSet Price TargetHold$25.00N/A
i
Rating by Ann Hynes at Mizuho
10/18/2019UBS GroupLower Price TargetSell$19.00 ➝ $18.00High
i
9/6/2019Bank of AmericaDowngradeNeutral ➝ Underperform$19.00High
i
8/27/2019Credit Suisse GroupLower Price TargetOutperform$30.00 ➝ $28.00High
i
8/5/2019BMO Capital MarketsLower Price TargetMarket Perform$32.00 ➝ $25.00Medium
i
8/2/2019MizuhoLower Price TargetNeutral$26.00 ➝ $24.00High
i
Rating by Ann Hynes at Mizuho
7/24/2019UBS GroupLower Price TargetSell$20.00Low
i
5/3/2019CitigroupSet Price TargetBuy$36.00Low
i
Rating by Ralph Giacobbe at Citigroup Inc.
4/11/2019Jefferies Financial GroupLower Price TargetIn-Line ➝ Hold$37.00 ➝ $31.00Medium
i
2/13/2019Credit Suisse GroupLower Price TargetOutperform ➝ Outperform$44.00 ➝ $42.00Low
i
2/8/2019MizuhoSet Price TargetHold$36.00Low
i
Rating by Ann Hynes at Mizuho
1/28/2019MizuhoReiterated RatingHold$38.00Low
i
1/14/2019CitigroupUpgradeNeutral ➝ Buy$34.88High
i
1/3/2019Deutsche Bank AktiengesellschaftInitiated CoverageHold ➝ Hold$34.00Medium
i
11/16/2018UBS GroupInitiated CoverageSell ➝ Sell$37.00Low
i
11/6/2018Credit Suisse GroupLower Price TargetOutperform ➝ Outperform$55.00 ➝ $50.00Medium
i
11/2/2018Robert W. BairdLower Price TargetNeutral ➝ Neutral$48.00 ➝ $40.00Low
i
11/2/2018BMO Capital MarketsLower Price TargetMarket Perform ➝ Market Perform$48.00 ➝ $43.00Low
i
10/19/2018Robert W. BairdLower Price TargetNeutral ➝ Neutral$50.00 ➝ $48.00Medium
i
9/24/2018SVB LeerinkUpgradeMarket Perform ➝ OutperformLow
i
Rating by A. Gupte at SVB Leerink LLC
9/18/2018Bank of AmericaUpgradeUnderperform ➝ Neutral$60.00 ➝ $50.00Low
i
8/3/2018Credit Suisse GroupUpgradeNeutral ➝ Outperform$47.00 ➝ $55.00High
i
8/2/2018Stifel NicolausSet Price TargetHold$47.00High
i
Rating by Chad Vanacore at Stifel Nicolaus
7/12/2018SVB LeerinkInitiated CoverageMarket Perform$50.00Low
i
5/7/2018Credit Suisse GroupLower Price TargetNeutral ➝ Neutral$57.00Low
i
5/4/2018CitigroupLower Price TargetNeutral ➝ Neutral$57.00 ➝ $50.00Low
i
3/27/2018Credit Suisse GroupInitiated CoverageNeutral$57.00Low
i
3/15/2018Jefferies Financial GroupSet Price TargetHold$58.00Low
i
Rating by Brian Tanquilut at Jefferies Financial Group Inc.
2/12/2018BMO Capital MarketsBoost Price TargetMarket Perform ➝ Market Perform$46.00 ➝ $58.00Low
i
2/12/2018JPMorgan Chase & Co.Boost Price TargetNeutral ➝ Neutral$46.00 ➝ $55.00Low
i
2/9/2018MizuhoReiterated RatingNeutral ➝ Neutral$49.00 ➝ $53.00Low
i
Rating by Ann Hynes at Mizuho
2/9/2018Robert W. BairdBoost Price TargetNeutral ➝ Neutral$48.00 ➝ $54.00Medium
i
2/8/2018StephensSet Price TargetBuy$62.00Medium
i
Rating by Dana Hambly at Stephens
2/6/2018Jefferies Financial GroupSet Price TargetHold$50.00Medium
i
Rating by Brian Tanquilut at Jefferies Financial Group Inc.
1/24/2018MizuhoSet Price TargetHold$49.00Low
i
Rating by Ann Hynes at Mizuho
1/24/2018Stifel NicolausReiterated RatingHold$56.00Low
i
12/21/2017SunTrust BanksSet Price TargetHold$55.00Medium
i
Rating by David S Macdonald at SunTrust Banks, Inc.
12/13/2017Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$58.00Low
i
11/3/2017CitigroupLower Price TargetNeutral$52.00 ➝ $47.00N/A
i
11/3/2017Robert W. BairdBoost Price TargetNeutral$47.00 ➝ $48.00N/A
i
11/3/2017Jefferies Financial GroupReiterated RatingHold$44.00N/A
i
Rating by Brian Tanquilut at Jefferies Financial Group Inc.
11/1/2017KeyCorpSet Price TargetBuy$51.00N/A
i
Rating by Jason Gurda at KeyCorp
10/16/2017BMO Capital MarketsInitiated CoverageMarket Perform$46.00N/A
i
10/3/2017Jefferies Financial GroupReiterated RatingHold$46.00Medium
i
Rating by Brian Tanquilut at Jefferies Financial Group Inc.
9/17/2017KeyCorpUpgradeSector Weight ➝ Overweight$51.00Low
i
9/3/2017Robert W. BairdReiterated RatingHold$47.00Medium
i
Rating by Whit Mayo at Robert W. Baird
8/1/2017MizuhoReiterated RatingNeutral$62.00 ➝ $48.00Medium
i
7/30/2017Jefferies Financial GroupSet Price TargetHold$53.00 ➝ $46.00Medium
i
Rating by Brian Tanquilut at Jefferies Financial Group Inc.
7/6/2017Jefferies Financial GroupReiterated RatingHold$50.00 ➝ $53.00Medium
i
6/22/2017StephensUpgradeEqual Weight ➝ Overweight$55.00 ➝ $68.00High
i
5/30/2017MizuhoLower Price TargetNeutral ➝ Neutral$64.00 ➝ $58.00Low
i
5/25/2017Stifel NicolausLower Price TargetHold$65.00 ➝ $58.00Low
i
5/4/2017Bank of AmericaDowngradeBuy ➝ UnderperformLow
i
4/26/2017Jefferies Financial GroupReiterated RatingHold$58.00Low
i
Rating by Brian Tanquilut at Jefferies Financial Group Inc.
4/10/2017Jefferies Financial GroupReiterated RatingHoldLow
i
Rating by Brian Tanquilut at Jefferies Financial Group Inc.
3/21/2017Robert W. BairdDowngradeOutperform ➝ Neutral$72.00High
i
3/10/2017JPMorgan Chase & Co.Reiterated RatingOverweight ➝ Neutral$69.00Low
i
2/8/2017Jefferies Financial GroupReiterated RatingHold$63.00N/A
i
Rating by Brian Tanquilut at Jefferies Financial Group Inc.
12/13/2016Jefferies Financial GroupDowngradeBuy ➝ Hold$75.00 ➝ $70.00N/A
i
12/9/2016The Goldman Sachs GroupInitiated CoverageNeutral$66.00N/A
i
11/9/2016MizuhoDowngradeBuy ➝ Neutral$69.00 ➝ $64.00N/A
i
10/28/2016MizuhoLower Price TargetBuy$79.00 ➝ $69.00N/A
i
10/27/2016Raymond JamesDowngradeOutperform ➝ Market PerformN/A
i
10/27/2016UBS GroupDowngradeOutperform ➝ Market PerformN/A
i
9/20/2016MizuhoReiterated RatingBuy$79.00N/A
i
8/26/2016Jefferies Financial GroupLower Price TargetBuy$80.00 ➝ $75.00N/A
i
Rating by Brian Tanquilut at Jefferies Financial Group Inc.
8/17/2016CitigroupLower Price TargetNeutral$76.00 ➝ $72.00N/A
i
7/29/2016JPMorgan Chase & Co.Lower Price TargetOverweight$85.00 ➝ $80.00N/A
i
6/8/2016Jefferies Financial GroupReiterated RatingBuy$80.00N/A
i
5/16/2016Robert W. BairdReiterated RatingBuyN/A
i
Rating by Whit Mayo at Robert W. Baird
4/29/2016Jefferies Financial GroupReiterated RatingBuyN/A
i
Rating by Brian Tanquilut at Jefferies Financial Group Inc.
4/29/2016MizuhoBoost Price TargetBuy$75.00 ➝ $79.00N/A
i
3/14/2016Piper Jaffray CompaniesReiterated RatingOverweight$76.00N/A
i
3/8/2016Stifel NicolausLower Price TargetBuy$81.00 ➝ $76.00N/A
i
3/7/2016Susquehanna BancsharesDowngradePositive ➝ Neutral$94.00 ➝ $70.00N/A
i
(Data available from 3/7/2016 forward)
MEDNAX logo
MEDNAX, Inc., together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology, and other pediatric subspecialty physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care services; and acute and chronic pain management services. The company also provides maternal-fetal care services, including inpatient and office-based clinical care to expectant mothers and their unborn babies through affiliated maternal-fetal medicine subspecialists, as well as obstetricians and other clinicians. In addition, it offers pediatric cardiology care services comprising inpatient and office-based pediatric cardiology care of the fetus, infant, child, and adolescent patients with congenital heart defects and acquired heart disease, as well as adults with congenital heart defects through affiliated pediatric cardiologist subspecialists and other related clinical professionals. Further, the company provides other pediatric subspecialty care services through pediatric subspecialists, such as pediatric intensivists, pediatric hospitalists, pediatric surgeons, pediatric ophthalmology, other newborn pediatric care, and newborn hearing screening program, as well as pediatric ear, nose, and throat physicians; and support services in the areas of hospitals, primarily in the pediatric emergency rooms, labor and delivery areas, and nursery and pediatric departments. Additionally, it offers consulting services to healthcare facilities and physicians. As of March 12, 2020, the company operated a network of approximately 4,325 physicians. MEDNAX, Inc. was founded in 1979 and is based in Sunrise, Florida.
Read More

Today's Range

Now: $26.04
$25.33
$26.30

50 Day Range

MA: $25.33
$20.82
$28.60

52 Week Range

Now: $26.04
$7.37
$29.25

Volume

1,259,735 shs

Average Volume

1,073,157 shs

Market Capitalization

$2.23 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.09

Frequently Asked Questions

What sell-side analysts currently cover shares of MEDNAX?

The following Wall Street research analysts have issued stock ratings on MEDNAX in the last twelve months: BMO Capital Markets, Cfra, Citigroup Inc., Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, Mizuho, Robert W. Baird, SunTrust Banks, Inc., TheStreet, Truist, UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for MD.

What is the current price target for MEDNAX?

10 Wall Street analysts have set twelve-month price targets for MEDNAX in the last year. Their average twelve-month price target is $18.95, suggesting a possible downside of 27.2%. Truist has the highest price target set, predicting MD will reach $26.00 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $14.00 for MEDNAX in the next year.
View the latest price targets for MD.

What is the current consensus analyst rating for MEDNAX?

MEDNAX currently has 2 sell ratings, 4 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in MD, but not buy more shares or sell existing shares.
View the latest ratings for MD.

What other companies compete with MEDNAX?

How do I contact MEDNAX's investor relations team?

MEDNAX's physical mailing address is 1301 CONCORD TERRACE, SUNRISE FL, 33323. The company's listed phone number is 954-384-0175 and its investor relations email address is [email protected] The official website for MEDNAX is www.mednax.com.